Dare Bioscience (DARE)
(Delayed Data from NSDQ)
$0.30 USD
0.00 (0.85%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $0.29 -0.01 (-2.46%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth A Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DARE 0.30 0.00(0.85%)
Will DARE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for DARE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DARE
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates
DARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Dare Bioscience, Inc. (DARE) Rating Upgrade to Strong Buy
Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock?
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates
Other News for DARE
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
Dare Bioscience announces it will receive payment of $1M under grant agreement
Biotech Alert: Searches spiking for these stocks today
Brookline gets more bearish on Dare Bioscience, downgrades shares
12 Health Care Stocks Moving In Wednesday's Intraday Session